Unknown

Dataset Information

0

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.


ABSTRACT: Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In preclinical studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis. In clinical studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a variety of hematologic malignancies, most notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), leading to US FDA approval for relapsed CLL and MCL. Ongoing studies are evaluating ibrutinib in other types of non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma and Waldenström's macrogobulinemia, in larger Phase III studies in CLL and MCL, and in combination studies with monoclonal antibodies and chemotherapy. Future studies will combine ibrutinib with other promising novel agents currently in development in hematologic malignancies.

SUBMITTER: Davids MS 

PROVIDER: S-EPMC4632638 | biostudies-other | 2014 May

REPOSITORIES: biostudies-other

altmetric image

Publications

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids Matthew S MS   Brown Jennifer R JR  

Future oncology (London, England) 20140501 6


Ibrutinib (formerly PCI-32765) is a potent, covalent inhibitor of Bruton's tyrosine kinase, a kinase downstream of the B-cell receptor that is critical for B-cell survival and proliferation. In preclinical studies, ibrutinib bound to Bruton's tyrosine kinase with high affinity, leading to inhibition of B-cell receptor signaling, decreased B-cell activation and induction of apoptosis. In clinical studies, ibrutinib has been well-tolerated and has demonstrated profound anti-tumor activity in a var  ...[more]

Similar Datasets

| S-EPMC4144824 | biostudies-literature
| S-EPMC8097726 | biostudies-literature
| S-EPMC7103514 | biostudies-literature
| S-EPMC7838594 | biostudies-literature
| S-EPMC4537012 | biostudies-literature
| S-EPMC9204102 | biostudies-literature
| S-EPMC5513110 | biostudies-literature
| S-EPMC5503608 | biostudies-literature
| S-EPMC8604242 | biostudies-literature
| S-EPMC9754806 | biostudies-literature